Abstract:Transition of acute kidney injury (AKI) to chronic kidney disease (CKD) represents an important cause of kidney failure. However, how AKI is transformed into CKD remains elusive. Following folic acid injury, mice developed AKI with ensuing CKD transition, featured by variable degrees of interstitial fibrosis and tubular cell atrophy and growth arrest. This lingering injury of renal tubules was associated with sustained oxidative stress that was concomitant with an impaired Nrf2 antioxidant defense, marked by mitigated Nrf2 nuclear accumulation and blunted induction of its target antioxidant enzymes, like heme oxygenase (HO)-1. Activation of the canonical Keap1/Nrf2 signaling, nevertheless, seems intact during CKD transition because Nrf2 in injured tubules remained activated and elevated in cytoplasm. Moreover, oxidative thiol modification and activation of Keap1, the cytoplasmic repressor of Nrf2, was barely associated with CKD transition. In contrast, glycogen synthase kinase (GSK)3β, a key modulator of the Keap1-independent Nrf2 regulation, was persistently overexpressed and hyperactive in injured tubules. Likewise, in patients who developed CKD following AKI due to diverse etiologies, like volume depletion and exposure to radiocontrast agents or aristolochic acid, sustained GSK3β overexpression was evident in renal tubules and coincided with oxidative damages, impaired Nrf2 nuclear accumulation and mitigated induction of antioxidant gene expression. Mechanistically, the Nrf2 response against oxidative insult was sabotaged in renal tubular cells expressing a constitutively active mutant of GSK3β, but reinforced by ectopic expression of dominant negative GSK3β in a Keap1-independent manner. In vivo in folic acid-injured mice, targeting GSK3β in renal tubules via conditional knockout or by weekly microdose lithium treatment reinstated Nrf2 antioxidant response in the kidney and hindered AKI to CKD transition. Ergo, our findings suggest that GSK3β-mediated Keap1-independent regulation of Nrf2 may serve as an actionable therapeutic target for modifying the long-term sequelae of AKI.

Nanoparticle-mediated Klotho Gene Therapy Prevents Acute Kidney Injury to Chronic Kidney Disease Transition Through Regulating PPARα Signaling in Renal Tubular Epithelial Cells

WCN24-732 NANOPARTICLE-MEDIATED DELIVERY OF KLOTHO PLASMIDS TO TUBULAR EPITHELIAL CELLS PROTECTS AGAINST RENAL FIBROSIS THROUGH FATTY ACID OXIDATION

Klotho-derived peptide 1 inhibits cellular senescence in the fibrotic kidney by restoring Klotho expression via posttranscriptional regulation

A Klotho-derived peptide protects against kidney fibrosis by targeting TGF-β signaling

Klotho retards renal fibrosis through targeting mitochondrial dysfunction and cellular senescence in renal tubular cells

Klotho Restoration Via Acetylation of Peroxisome Proliferation–Activated Receptor Γ Reduces the Progression of Chronic Kidney Disease

Multifunctional Natural Polymer Nanoparticles as Antifibrotic Gene Carriers for CKD Therapy

lSelf‐assembling P38 Peptide Inhibitor Nanoparticles Ameliorate the Transition from Acute to Chronic Kidney Disease by Suppressing Ferroptosis

Klotho protein has therapeutic activity in contrast-induced acute kidney injury by limiting NLRP3 inflammasome-mediated pyroptosis and promoting autophagy

Size and Temporal-Dependent Efficacy of Oltipraz-Loaded PLGA Nanoparticles for Treatment of Acute Kidney Injury and Fibrosis

αKlotho protein has therapeutic activity in contrast-induced acute kidney injury by limiting NLRP3 inflammasome-mediated pyroptosis and promoting autophagy

Klotho Regulates Epithelial-to-Mesenchymal Transition in Vitro Via Wnt/β-Catenin Pathway and Attenuates Chronic Allograft Dysfunction in a Rat Renal Transplant Model.

Self‐Assembling P38 Peptide Inhibitor Nanoparticles Ameliorate the Transition from Acute to Chronic Kidney Disease by Suppressing Ferroptosis (Adv. Healthcare Mater. 23/2024)

Klotho ameliorates diabetic nephropathy by activating Nrf2 signaling pathway in podocytes

Klotho-derived peptide KP1 ameliorates SARS-CoV-2-associated acute kidney injury

Klotho Inhibits PKCα/p66SHC-mediated Podocyte Injury in Diabetic Nephropathy

Klotho inhibits renal ox-LDL deposition via IGF-1R/RAC1/OLR1 signaling to ameliorate podocyte injury in diabetic kidney disease

A Mn 3 O 4 -Based Antioxidant Nanoplatform Loaded with Tacrolimus to Ameliorate Chronic Kidney Disease by Reducing Inflammation and Oxidative Stress

The Protective Function of Αklotho in Chronic Kidney Disease: Evidence and Therapeutic Implications

GSK3β-mediated Keap1-independent regulation of Nrf2 antioxidant response: A molecular rheostat of acute kidney injury to chronic kidney disease transition

A Peptide from Yak Ameliorates Hypoxia-Induced Kidney Injury by Inhibiting Inflammation and Apoptosis Via Nrf2 Pathway